文献速递胸部肿瘤

手术切除联合术中热灌注顺铂与吉西他滨治疗胸膜间皮瘤的I期试验

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2018-05-09

该单中心I期试验旨在确定恶性胸膜间皮瘤切除后术中热灌注化疗中吉西他滨联合顺铂的最大耐受剂量。2007至2011年入组141例,104例完成治疗;剂量限制性毒性为3级白细胞减少,见于2例接受1100 mg/m2吉西他滨的患者,最大耐受剂量定为吉西他滨1000 mg/m2联合顺铂175 mg/m2。结论为联合方案在完全手术切除背景下安全可行。

要点

  • 最大耐受剂量:吉西他滨1000 mg/m2联合顺铂175 mg/m2。
  • 剂量限制性毒性为3级白细胞减少,见于1100 mg/m2吉西他滨组2例。
  • 完成治疗患者中位总生存20.3个月,无复发生存10.7个月。

核心结论

  • 顺铂联合吉西他滨术中热灌注化疗在胸膜间皮瘤完全手术切除(EPP或P/D)背景下可安全可行地实施。

研究设计与样本

  • 单中心I期临床试验,采用3+3设计,吉西他滨从100 mg/m2起始、100 mg增量递增,联合固定腔内顺铂(175-225 mg/m2范围)及全身细胞保护。
  • 2007至2011年入组141例,104例完成治疗;EPP组59例,P/D组41例。

主要发现

  • 完成治疗患者中位年龄65岁(范围43-85岁),女性22例(21%)。
  • EPP组31例(53%)为上皮样组织学类型,中位影像学肿瘤体积236 cm3(范围16-4285 cm3);P/D组29例(71%)为上皮样型,中位肿瘤体积79 cm3(范围6-1107 cm3)。
  • 手术死亡率为2%;EPP组27例(46%)发生35起严重不良事件,P/D组16例(39%)发生22起严重不良事件。
  • 剂量限制性毒性为3级白细胞减少,见于2例接受1100 mg/m2吉西他滨的患者。
  • 完成治疗患者中位总生存20.3个月,中位无复发生存10.7个月。

关键数值与推荐

  • 最大耐受剂量确定为吉西他滨1000 mg/m2联合顺铂175 mg/m2。
  • 剂量限制性毒性为3级白细胞减少,发生于1100 mg/m2吉西他滨剂量组2例患者。

临床怎么用

  • 对于适合完全宏观切除的恶性胸膜间皮瘤患者,可考虑在EPP或P/D术中行顺铂联合吉西他滨热灌注化疗。
  • 推荐吉西他滨剂量为1000 mg/m2联合顺铂175 mg/m2,需注意3级白细胞减少风险。

局限性

  • 单中心I期试验,样本量有限,主要目的为确定最大耐受剂量而非疗效比较。
  • EPP与P/D分组基于研究者对患者体能和可切除性的评估,非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The primary objective of this single-institution phase I clinical trial was to establish the maximum tolerated dose of gemcitabine added to cisplatin and delivered as heated intraoperative chemotherapy after resection of malignant pleural mesothelioma. METHODS: The extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators' assessment of patient fitness and potential for macroscopic complete resection. Previously established intracavitary dosing of cisplatin (range 175-225 mg/m2) with systemic cytoprotection was used in combination with escalating doses of gemcitabine, following a 3-plus-3 design from 100 mg/m2 in 100-mg increments. RESULTS: From 2007 to 2011, 141 patients were enrolled and 104 completed treatment. The median age of those completing treatment was 65 years (range 43-85 years), and 22 (21%) were female. In the EPP arm (n = 59), 31 patients (53%) had the epithelioid histologic type and the median radiographic tumor volume was 236 cm3 (range 16-4285 cm3). In the P/D arm (n = 41), 29 patients (71%) had the epithelioid histologic type and the median tumor volume was 79 cm3 (range 6-1107 cm3). The operative mortality rate was 2%, and 35 and 22 serious adverse events were encountered among 27 patients (46%) and 16 patients (39%) in the EPP and P/D arms, respectively. Dose-limiting toxicity (grade 3 leukopenia) was observed in two patients who were receiving 1100 mg/m2 of gemcitabine, thus establishing the maximum tolerated dose at 1000 mg/m2, in combination with 175 mg/m2 of cisplatin. The median overall and recurrence-free survival times in treated patients were 20.3 and 10.7 months, respectively. CONCLUSIONS: Combination cisplatin and gemcitabine heated intraoperative chemotherapy can be administered safely and feasibly in the context of complete surgical resection of malignant pleural mesothelioma by EPP or P/D.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Burt BM, Richards WG, Lee HS, et al. A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018. PMID: 29753120. doi:10.1016/j.jtho.2018.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。